Datavault AI's proposed 19.9% stake and expanded technology license could extend use of its tools, while DataMEDS would pay to bring them to market. Datavault keeps its technology, but the proposal is nonbinding, still needs review and final agreements, and may close in Q4 2026.
This could give Datavault a larger role in a healthcare platform and extend use of its technology without giving up ownership. DataMEDS would pay the costs of bringing the tools to market. The proposal is not binding and still needs review and final agreements. A possible close is expected in Q4 2026, so the benefit is not secured.
The proposed technology could add patient-data and medication tools to DataMEDS's platform, but DataMEDS would pay the costs of bringing them to market. Because the deal is nonbinding and no business results are reported, this does not yet change its outlook.
Follow Datavault AI (DVLT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DVLT